Apo E variants in patients with type III hyperlipoproteinemia

Atherosclerosis

Volumn 127, Issue 2, 1996, Pages 273-282

  Civeira, Fernando ^a   Pocoví, Miguel ^b   Cenarro, Ana ^b   Casao, Elena ^b   Vilella, Elisabet ^c   Joven, Jordi ^c   González, José ^b   Garcia Otín, Angel L ^b   Ordoväs, José M ^d  

^a HOSPITAL ROYO VILLANOVA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d TUFTS UNIVERSITY   (United States)

Author keywords

Apo E genotyping; apo E polymorphisms; Apo E(Christchurch); apolipoprotein E; dysbetalipoproteinemia; type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CATABOLISM; DNA SEQUENCE; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERLIPOPROTEINEMIA; MAJOR CLINICAL STUDY; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR BINDING;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEINS E; DNA; DNA PROBES; FEMALE; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; ISOELECTRIC FOCUSING; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; SPAIN;

EID: 0030596002     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05969-2     Document Type: Article

References (48)

1. [1] Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS Valle D. (eds). The Metabolic Basis of Inherited Disease, 6th edn, New York: Mc Graw-Hill;1989:1195.
2. [2] Mahley RW, Innerarity TL, Rall SC, Weisgraber KH. Plasma lipoproteins, apolipoprotein structure and function. J Lipid Res 1984;5:1277.
3. [3] Ji Z-S, Fazio S, Le Y-L, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem 1994;269:2764.
4. [4] Barter P. High-density lipoproteins and reverse cholesterol transport. Curr Opin Lipidol 1993;4:210.
5. [5] Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991;252:1817.
6. [6] Innerarity TL, Friedlander ET, Rall SC, Weisgraber KH, Mahley RW. The receptor binding domain of human apolipoprotein E: binding of apolipoprotein E fragments. J Biol Chem 1983;258:12341.
7. [7] Utermann G, Hess M, Steinmetz A. Polymorphism of apo E and occurrence of dysbetalipoproteinemia in man. Nature 1977;269:604.
8. [8] Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1.
9. [9] Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer MM, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apo E1 and apo E5 isoforms. J Lipid Res 1987;28:371.
10. [10] Schaefer EJ, Lamon-Fava S, Johnson S et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: results from the Framingham Offspring Study. Arterioscler Thromb 1994;14:1105.
11. [11] Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA 1994;272:1666.
12. [12] Poirier J, Davignon J, Bouthellier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease, Lancet 1993;342:697.
13. [13] Myers RH, Schaefer EJ, Wilson PWF et al. Apolipoprotein E ∈4 association with dementia in a population-based study: The Framingham study. Neurology 1996;46:673.
14. [14] Kervinen K, Savolainen MJ, Salokannel J et al. Apolipoprotein E and B polymorphisms - longevity factors assessed in nonagenarians. Atherosclerosis 1994;105:85.
15. [15] Haviland MB, Lussier-Cacan S, Davignon J, Sing CF. Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Am J Med Genet 1995;58:315.
16. [16] Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis 1995;118:S11.
17. [17] Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433.
18. [18] Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31:545.
19. [19] Kontula K, Aalto-Setälä K, Kuusi T, Hämäläinen L, Syvänen AC. Apolipoprotein E polymorphism determined by restriction enzyme analysis of DNA amplified by polymerase chain reaccleavage tion: convenient alternative to phenotyping by isolectric focucleavage sing. Clin Chem 1990;36:2087.
20. [20] Weisgraber KH, Newhouse YM, Mahley RW. Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide probes. Biochem Biophys Res Commun 1988;157:1212.
21. [21] Hansen PS, Gerdes LU, Klausen IC, Gregersen N, Faergeman O. Genotyping compared with protein phenotyping of the common apolipoprotein E polymorphism. Clin Chim Acta 1994;224:131.
22. [22] Civeira F, Pocoví M, Moreda A, Alamillo J, Cía P, Grande F. Niveles de colesterol y triglicéridos, y distribuciön del colesterol en lipoproteínas en una población laboral. Varones Clin Invest Arteriosclerosis 1990;2:43.
23. [23] Moreda A, Alamillo J, Pocoví M, Civeira F, Blasco M, Ordovás JM. Nivelés de colesterol y triglicéridos, y distribución del colesterol en lipoproteinas en una población laboral. Mujeres Clin Invest Arteriosclerosis 1990;2:48.
24. [24] The Expert Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Ann Int Med 1988;148:36.
25. [25] Havel RJ, Eder HA, Bragdon JH. Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345.
26. [26] Vilella E, Joven J, Fernández M et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 1993;34:1555.
27. [27] Zhao SP, Smelt AHM, Gevers-Leuven JA, van den Maagdenberg AMJM, van der Laarse A, van't Hooft FM. Lipoproteins in familial dysbetalipoproteinemia. Variation of serum cholesterol level associated with VLDL concentration. Arterioscler Thromb 1993;13:316.
28. [28] Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor binding activity of human apoprotein due to cysteine-arginine interchange at single site. J Biol Chem 1982;257:2518.
29. [29] Rall SC, Weisgraber KH, Innerarity TL, Bersot TP, Mahley RW, Blum CB. Identification of a new structural variant of human apolipoprotein E, E2 (Lys 146 → Gln) in a type III hyperlipoproteinemic subject with the E3/E2 phenotype. J Clin Invest 1993;72:1288.
30. [30] Wardell MR, Brennan SO, Janus ED, Fraser R, Carrell RW. Apolipoprotein E2-Christchurch (136Arg → Ser). New variant of human apolipoprotein E in patients with type III hyperlipoproteinemia. J Clin Invest 1987;80:483.
31. [31] Pocovi M, Cenarro A, Civeira F, Myers RH, Casao E, Esteban M, Ordovas JM. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Argl 36 → Ser) variant in multigenerational pedigree studies. Atherosclerosis 1996;122:33.
32. [32] Rall SC, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA 1982;79:4696.
33. [33] Mann WA, Gregg RE, Sprecher DL, Brewer HB Jr. Apolipoprotein E-1 Harrisburg a new variant of apo E dominantly associated with type III hyperlipoproteinemia. Biochim Biophys Acta 1989;1005:239.
34. [34] Rall SC Jr, Newhouse YM, Clarke HRG, Weisgraber KH, McCarthy BJ, Mahley RW, Bersot TP. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/E3. Structure and genetics of an apolipoprotein variant. J Clin Invest 1989;83:1095.
35. [35] Wardell MR, Weisgraber KH, Havekes LM, Rall SC Jr. Apolipoprotein E3 Leiden contains a seven amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem 1989;264:21-205.
36. [36] Weisgraber KH, Rall SC Jr, Innerarity TL, Mahley RW, Kuusi T, Elnholm C. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1. J Clin Invest 1984;73:1024.
37. [37] Lahoz C, Osgood D, Wilson PWF, Scheafer EJ, Ordovas JM. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem 1996 (in press).
38. [38] de Knijff P, van den Maagdenberg JM, Stalenhoef AFH et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991;88:643.
39. [39] Havel RJ, Kotite L, Kane JP, Tun P, Bersot T. A typical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J Clin Invest 1983;72:379.
40. 145 → Cys). Homozygosity for rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J Biol Chem 1991;266:10 479.
41. 145 → Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. J Biol Chem 1992;267:13 642.
42. [42] Richard P, Pascual de Zulueta M, Beucler I, De Gennes J-L, Cassaigne A, Iron A. Identification of a new apolipoprotein E variant (E2 Arg142 → Leu) in type III hyperlipidemia. Atherosclerosis 1995;112:19.
43. [43] Lalazar A, Ou SI, Mahley RW. Human apolipoprotein E. Receptor binding activity of truncated variants with carboxyl terminal delections. J Biol Chem 1989;264:8447.
44. [44] Mann WA, Lohse P, Gregg RE et al. Dominant expression of type III hyperlipoproteinemia. Pathophysiologicat insights derived from the structural and kinetic characteristics of apo E-1(Lys146 → Glu). J Clin Invest 1995;96:1100.
45. [45] Innerarity TL, Weisgraber KH, Arnold KS, Rall SC Jr, Mahley RW. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem 1984;259:7261.
46. [46] Kitahara M, Shinomiya M, Shirai K, Saito Y, Yoshida S. Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese. Atherosclerosis 1990;82:197.
47. [47] Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apo E phenotype: a meta-analysis. J Lipid Res;33:447.
48. [48] Hopkins PN, Wu LL, Schumacher MC et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb 1991;11:1137.